Product Information
QUILLIVANT XR 25 MG/5 ML SUSP is a brand product labeled by NextWave Pharmaceuticals, Inc, priced at $1.8006 per ML under NDC 24478032406. Its NADAC has been published 415 times since Oct 24, 2018.
FDA first approved this application on Sep 27, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
900 mg/180mL
Manufacturer
NextWave Pharmaceuticals, IncNDC
24478032406
Classification
Brand
Dosage Form
SUSPENSION, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA202100FDA Approved
9/27/2012
TE Code
AB
On Market Since
1/4/2013
Pharmacological Classes
Price Statistics
The NADAC for QUILLIVANT XR 25 MG/5 ML SUSP has been published 415 times since Oct 24, 2018, and over the history we have for it it has risen 23.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8006 per ML |
|---|---|
| All-time high | $1.8105 (Mar 13, 2024) |
| All-time low | $1.4576 (Oct 24, 2018) |
| 52-week high | $1.8065 |
| 52-week low | $1.8006 |
| Median price | $1.8050 |
| Average price | $1.7338 |
| Largest weekly change | +9.9% (Jan 8, 2020) |
| Weeks tracked | 415 |
| Tracking since | Oct 24, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the methylphenidate hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
NextWave Pharmaceuticals, Inc manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QUILLIVANT XR 25 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for QUILLIVANT XR 25 MG/5 ML SUSP, manufactured by NextWave Pharmaceuticals, Inc, is $1.8006 per ML (NDC 24478032406), effective Sep 30, 2026.
How has the price of QUILLIVANT XR 25 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for QUILLIVANT XR 25 MG/5 ML SUSP has risen 23.5%. It has been tracked across 415 weekly CMS publications since Oct 24, 2018.
What are the highest and lowest recorded NADAC prices for QUILLIVANT XR 25 MG/5 ML SUSP?
Since Oct 24, 2018, the NADAC for QUILLIVANT XR 25 MG/5 ML SUSP has ranged from a low of $1.4576 (Oct 24, 2018) to a high of $1.8105 (Mar 13, 2024), with a median of $1.8050 per ML.
Are there cheaper alternatives to QUILLIVANT XR 25 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of QUILLIVANT XR 25 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QUILLIVANT XR 25 MG/5 ML SUSP?
QUILLIVANT XR 25 MG/5 ML SUSP (NDC 24478032406) is labeled by NextWave Pharmaceuticals, Inc, and CMS classifies it as a brand product.